Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026 Orchestra BioMed and ...
Orchestra BioMed (Nasdaq:OBIO) announced updated expectations for the timeline of its BACKBEAT cardiac pacing clinical trial.
1d
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026Medtronic (NYSE: MDT) ...
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +16.98% and -94.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for ...
Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) evaluating Atrioventricular Interval ...
Orchestra BioMed (Nasdaq:OBIO) announced today that it secured $35 million in total funding through partnerships with ...
Orchestra BioMed has announced that the FDA has granted Breakthrough Device Designation for its atrioventricular interval modulation (AVIM) therapy, aimed at treating over 7.7 million U.S. patients ...
Biomed Industries, Inc. Advances Dual-Track Obesity Therapy Strategy with Near-Term Revenue from Bioxentra Life ...
- BioMed Realty Continues to Support California’s Life Science Industry Growth with $2.6 Billion Capital Commitments in Last Four Years SAN DIEGO--(BUSINESS WIRE)--BioMed Realty (“BioMed”), a leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results